Alnylam Pharmaceuticals (ALNY) PT Lowered to $111 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $162.14 +1.41%
Rating Summary:
26 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
26 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Stifel analyst Paul Matteis lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $111.00 (from $117.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Procore Technologies, Inc (PCOR) PT Raised to $85 at Stifel
- Truist Securities Downgrades Alnylam Pharmaceuticals (ALNY) to Hold
- RxSight Inc. (RXST) PT Lowered to $5 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
